featured
Radiotherapy With Cetuximab or Durvalumab for Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
Lancet Oncol 2024 Dec 01;25(12)1576-1588, LK Mell, PA Torres-Saavedra, SJ Wong, JA Kish, SS Chang, RC Jordan, T Liu, MT Truong, EW Winquist, V Takiar, T Wise-Draper, JR Robbins, CP Rodriguez, MJ Awan, BM Beadle, C Henson, S Narayan, SA Spencer, S Powell, N Dunlap, AG Sacco, KS Hu, HS Park, JE Bauman, J Harris, SS Yom, QT LeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.